1. |
Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet, 2017, 390(10089): 73-84.
|
2. |
Navarro-Compán V, Sepriano A, El-Zorkany B, et al. Axial spondyloarthritis. Ann Rheum Dis, 2021, 80(12): 1511-1521.
|
3. |
Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis, 2009, 68(Suppl 2): 1-44.
|
4. |
López-Medina C, Moltó A. Update on the epidemiology, risk factors, and disease outcomes of axial spondyloarthritis. Best Pract Res Clin Rheumatol, 2018, 32(2): 241-253.
|
5. |
吴珊珊, 段振华, 潘发明. 强直性脊柱炎流行病学研究进展. 安徽医科大学学报, 2013, 48(8): 988-992.
|
6. |
黄烽, 朱剑, 王玉华, 等. 强直性脊柱炎诊疗规范. 中华内科杂志, 2022, 61(8): 893-900.
|
7. |
Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol, 2019, 71(10): 1599-1613.
|
8. |
Danve A, Deodhar A. Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol, 2022, 18(4): 205-216.
|
9. |
Lubrano E, De Socio A, Perrotta FM. Unmet needs in axial spondyloarthritis. Clin Rev Allergy Immunol, 2018, 55(3): 332-339.
|
10. |
Toussirot E. The use of Janus kinase inhibitors in axial spondyloarthritis: current insights. Pharmaceuticals (Basel), 2022, 15(3): 270.
|
11. |
《Janus激酶抑制剂治疗风湿免疫病超药品说明书用药中国专家共识》制定专家组. Janus激酶抑制剂治疗风湿免疫病超药品说明书用药中国专家共识. 中华风湿病学杂志, 2023, 27(1): 1-9.
|
12. |
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum, 1984, 27(4): 361-368.
|
13. |
Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis, 2009, 68(6): 777-783.
|
14. |
van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis, 2017, 76(8): 1340-1347.
|
15. |
Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis, 2021, 80(8): 1004-1013.
|
16. |
姜克悦, 刘磊, 王文惠. 枸橼酸托法替布治疗活动性强直性脊柱炎的随机对照研究. 实用医学杂志, 2022, 38(11): 1415-1418.
|
17. |
van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet, 2019, 394(10214): 2108-2117.
|
18. |
van der Heijde D, Baraliakos X, Sieper J, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis, 2022, 81(11): 1515-1523.
|
19. |
van der Heijde D, Baraliakos X, Gensler LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet, 2018, 392(10162): 2378-2387.
|
20. |
Deodhar A, Van den Bosch F, Poddubnyy D, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2022, 400(10349): 369-379.
|
21. |
Winthrop KL, Cohen SB. Oral surveillance and JAK inhibitor safety: the theory of relativity. Nat Rev Rheumatol, 2022, 18(5): 301-304.
|
22. |
Mattay SS, Zamani M, Saturno D, et al. Risk of major adverse cardiovascular events in immune-mediated inflammatory disorders on biologics and small molecules: network meta-analysis. Clin Gastroenterol Hepatol, 2024, 22(5): 961-970.
|
23. |
McHugh J. Cancer and cardiovascular risk with JAK inhibition. Nat Rev Rheumatol, 2023, 19(2): 64.
|
24. |
Cohen SB. JAK inhibitors and VTE risk: how concerned should we be. Nat Rev Rheumatol, 2021, 17(3): 133-134.
|
25. |
McInnes IB, Szekanecz Z, McGonagle D, et al. A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition. Rheumatology (Oxford), 2022, 61(5): 1783-1794.
|
26. |
Li S, Li F, Mao N, et al. Efficacy and safety of Janus kinase inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis. Eur J Intern Med, 2022, 102: 47-53.
|
27. |
Lee YH, Song GG. Janus kinase inhibitors for treating active ankylosing spondylitis: a meta-analysis of randomized controlled trials. Z Rheumatol, 2022, 81(1): 71-76.
|